SKPO yields 70422.54% · ABBV yields 3.06%● Live data
📍 SKPO pulled ahead of the other in Year 1
Combined, SKPO + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SKPO + ABBV for your $10,000?
Skye Petroleum, Inc. provides production chemical treatment services to oil companies in the United States. It offers production chemicals, which include solvents, dispersants, and wax inhibitors; cleaning compounds, such as degreasers; coiled tubing, including lubricants, scale control inhibitor products, viscosifiers, iron control agents, oxygen scavengers, H2S control scavengers, and corrosion inhibitors; and foamers. The company also offers surfactants, iron control additives, gel stabilizers, friction reducers, breakers, biocides, cross-linkers, and buffers for fracturing operations; and drilling and complexion fluid issues. It provides its technology for use in various applications, such as oil wells, flow lines, tanks, tubing, tank bottoms, and any surface, or sub-surface equipment to solve flow assurance issues related to paraffin, asphaltene, and sludge. The company was formerly known as National Equities Holdings, Inc. and changed its name to Skye Petroleum, Inc. in April 2010. The company was founded in 1987 and is based in Sugar Land, Texas.
Full SKPO Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.